Treatment of Paroxysmal Dyskinesia.
MR-1
PED
PKD
PNKD
PRRT2
Paroxysmal dyskinesia
SLC2A1
Treatment
Journal
Neurologic clinics
ISSN: 1557-9875
Titre abrégé: Neurol Clin
Pays: United States
ID NLM: 8219232
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
entrez:
14
4
2020
pubmed:
14
4
2020
medline:
22
9
2020
Statut:
ppublish
Résumé
Paroxysmal dyskinesia (PxD) is a heterogeneous group of syndromes characterized by recurrent attacks of abnormal movements, triggered by detectable factors, without loss of consciousness. According to the precipitating factors, they are classified as paroxysmal kinesigenic dyskinesia (PKD), paroxysmal non-kinesigenic dyskinesia (PNKD), and paroxysmal exercise-induced dystonia (PED). PxD treatment is based on the combination of nonpharmacologic and pharmacologic approaches. Pharmacologic and nonpharmacologic treatments effective for PNKD and PED also are available. In PxD refractory to conventional treatment, surgery might be an alternative therapeutic option. The course of PRRT2-PKD and MR-1-PNKD is benign, and treatment might not be needed with advancing age.
Identifiants
pubmed: 32279719
pii: S0733-8619(20)30007-4
doi: 10.1016/j.ncl.2020.01.007
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
433-447Informations de copyright
Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures K.P. Bhatia holds research grants from NIHRRfPB, MRC Wellcome Strategic grant (Ref. no.: WT089698), and PD UK (Ref. no.: G-1009) and has received honoraria/financial support to speak/attend meetings from GSK, Boehringer-Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva Lundbeck and Orion pharmaceutical companies. K.P. Bhatia receives royalties from Oxford University Press and a stipend for MDCP editorship. A. Latorre has nothing to disclose.